VOTIS Subdermal Imaging Technologies

Company Overview

Snapshot

Founded in June 2017 by Merrill Weber, VOTIS Subdermal Imaging Technologies operates with 11–50 employees. The company has secured $8.07 million in total capital raised across 6 funding rounds from 2 investors.

Business overview

VOTIS Subdermal Imaging Technologies develops a suite of non-invasive medical devices to help individuals with Peripheral Artery Disease (PAD) preserve their feet. Their core products include PedCheck for screening asymptomatic patients, PedStage for monitoring disease progression and treatment impact, and PedFlo for informing physicians about blood flow during revascularization procedures. These devices utilize imaging technology to assess blood flow and oxygen levels within the foot, serving the healthcare industry, particularly hospitals and clinics, with diagnostic and decision support tools. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices, Diagnostics Devices, and Digital Healthcare, leveraging artificial intelligence and cloud-based software.

Strategic signal

In May 2022, VOTIS Subdermal Imaging Technologies announced the enrollment of the first human subject in a pilot feasibility study for its PedCheck device at Hadassah Medical Center in Jerusalem. This event is significant as it marks a crucial step in the clinical validation of their non-invasive technology for early detection of Peripheral Arterial Disease (PAD). For investors, this signals progress towards regulatory clearance and commercialization, demonstrating the company's commitment to bringing its innovative diagnostic solutions to market and addressing a critical need in patient care.

Company Intelligence Q&A

What is VOTIS Subdermal Imaging Technologies' primary focus?

VOTIS Subdermal Imaging Technologies focuses on developing non-invasive medical devices for the assessment and management of Peripheral Artery Disease (PAD), aiming to preserve the feet of affected individuals.

When was VOTIS Subdermal Imaging Technologies founded?

VOTIS Subdermal Imaging Technologies was founded in June 2017.

What significant clinical milestone did VOTIS Subdermal Imaging Technologies achieve in May 2022?

In May 2022, VOTIS Subdermal Imaging Technologies enrolled the first human subject in a pilot feasibility study for its PedCheck device at Hadassah Medical Center in Jerusalem, testing its feasibility, usability, and safety.

Which organization did VOTIS Subdermal Imaging Technologies partner with in December 2020?

In December 2020, VOTIS Subdermal Imaging Technologies announced plans with ii Ventures Private Limited to develop preventative medicine devices to screen for Peripheral Artery Disease in India.

What technology did VOTIS Subdermal Imaging Technologies license in October 2020?

In October 2020, VOTIS Subdermal Imaging Technologies licensed vascular optical tomographic imaging (VOTI) technology from Columbia University to develop medical devices for PAD patients.